Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial - Nature Medicine

United States News News

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial - Nature Medicine
United States Latest News,United States Headlines
  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 57 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 53%

For infants with three copies of SMN1 at risk for SMA type 1, onasemnogene abeparvovec improves ventilator-free survival and nutritional/respiratory independence and allows motor development similar to healthy children without SMA. 2022SMAConference

gene modifier variant would not be included in the ITT population. Efficacy and safety findings for children with threeSMN2

who met the ITT criteria and were ≤6 weeks of age at the time of gene replacement therapy . Full eligibility criteria are described in the Supplementary Material. The Coronavirus Disease 2019 pandemic did not affect retention. No participant withdrew from SPR1NT or was lost to follow-up because of the COVID-19 pandemic. However, some scheduled study visits and assessments were delayed or cancelled because of restrictions caused by the COVID-19 pandemic.All children were admitted into the hospital for pretreatment baseline procedures 1 day before infusion. For all assessments, baseline was defined as the last assessment conducted before dosing.

Outpatient follow-up assessments were conducted on Days 7, 14, 21, 30, 44, 51 , 60, and 72 post-dose, and then at 3 months of age and every 3 months thereafter through 24 months of age . All eligible children were invited to enroll in an ongoing long-term follow-up study .The primary efficacy endpoint was the ability to stand independently for ≥3 seconds at any visit up to 24 months of age, as stipulated by item #40 from the gross motor subtest of the BSID.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NatureMedicine /  🏆 451. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Cancer’s clock, data hoarding — the week in infographicsCancer’s clock, data hoarding — the week in infographicsNature highlights three key graphics from the week in science and research.
Read more »

Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa - Nature MedicineGenomic characterization of SARSCoV2 Omicron lineages BA.4 and BA.5 shows continued viral diversification, providing mechanistic insights into the ability of new lineages to outcompete predecessors. houzhou Tuliodna ceri_news krisp_news nicd_sa
Read more »

Brain lesions disrupting addiction map to a common human brain circuit - Nature MedicineBrain lesions disrupting addiction map to a common human brain circuit - Nature MedicineLesions resulting in addiction remission occur in multiple different brain locations but map to a specific brain circuit. JJoutsa and foxmdphd from UniTurku and harvardmed
Read more »

New wearable offers extra support for those with physical disabilitiesNew wearable offers extra support for those with physical disabilitiesThe research data showed that the device increased endurance by about a third in the healthy subjects and by roughly 60% in the participant with muscular dystrophy.
Read more »

‘Should never be used for sleep’: CPSC shares warning after at least 13 rocker-related deaths‘Should never be used for sleep’: CPSC shares warning after at least 13 rocker-related deathsThe new Safety Standard for Infant Sleep Products, makes it unlawful to sell non-compliant infant sleep products, and applies to products manufactured on or after June 23rd.
Read more »



Render Time: 2025-02-22 23:29:42